Targeting inflammation: impact on atherothrombosis (Q38170328)

30 August 2017

Targeting inflammation: impact on atherothrombosis (English)

1 reference

30 August 2017

Luigi Marzio Biasucci

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24327329%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

author name string

Maria Giulia Marini

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24327329%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

Chiara Sonnino

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24327329%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

Marco Previtero

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24327329%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

language of work or name

English

0 references

publication date

11 December 2013

1 reference

Journal of Cardiovascular Translational Research

30 August 2017

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24327329%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

volume

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24327329%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

page(s)

9-18

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24327329%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

issue

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24327329%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1007/s12265-013-9523-7

10 June 2020

exact match

0 references

cites work

Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010

1 reference

https://api.crossref.org/works/10.1007%2FS12265-013-9523-7

Inflammation in atherosclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12265-013-9523-7

Monocytes in atherosclerosis: subsets and functions

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12265-013-9523-7

Inflammation in atherosclerosis: from pathophysiology to practice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12265-013-9523-7

Inflammation, atherosclerosis, and coronary artery disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12265-013-9523-7

Relation of platelet and leukocyte inflammatory transcripts to body mass index in the Framingham heart study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12265-013-9523-7

Heat-shock protein 60-reactive CD4+CD28null T cells in patients with acute coronary syndromes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12265-013-9523-7

Unusual CD4+CD28null T lymphocytes and recurrence of acute coronary events

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12265-013-9523-7

Interleukin-17 and type 17 helper T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12265-013-9523-7

Emerging role of IL-17 in atherosclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12265-013-9523-7

Human regulatory T cells: role in autoimmune disease and therapeutic opportunities

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12265-013-9523-7

The opposite-direction modulation of CD4+CD25+ Tregs and T helper 1 cells in acute coronary syndromes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12265-013-9523-7

Monoclonal T-cell proliferation and plaque instability in acute coronary syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12265-013-9523-7

Metabolic and scintigraphic studies of radioiodinated human C-reactive protein in health and disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12265-013-9523-7

Elevated levels of C-reactive protein at discharge in patients with unstable angina predict recurrent instability

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12265-013-9523-7

Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12265-013-9523-7

C-reactive protein concentration and risk of coronary heart disease, stroke, and mortality: an individual participant meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12265-013-9523-7

Low-dose aspirin for the prevention of atherothrombosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12265-013-9523-7

Cardioprotective effects of carvedilol on acute autoimmune myocarditis: anti-inflammatory effects associated with antioxidant property

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12265-013-9523-7

Irbesartan significantly reduces C reactive protein concentrations after 1 month of treatment in unstable angina

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12265-013-9523-7

Telmisartan: just an antihypertensive agent? A literature review

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12265-013-9523-7

Comparison of the effects of ramipril versus telmisartan on high-sensitivity C-reactive protein and endothelial progenitor cells after acute coronary syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12265-013-9523-7

Effects of an angiotensin-converting enzyme inhibitor (ramipril) on inflammatory markers in secondary prevention patients: RAICES Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12265-013-9523-7

Effect of angiotensin-converting enzyme inhibition on C-reactive protein levels: the ramipril C-reactive pRotein randomized evaluation (4R) trial results

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12265-013-9523-7

Interleukin-1 plays a major role in vascular inflammation and atherosclerosis in male apolipoprotein E-knockout mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12265-013-9523-7

Lack of interleukin-1 receptor antagonist modulates plaque composition in apolipoprotein E-deficient mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12265-013-9523-7

The role of IL-1 in the pathogenesis of heart disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12265-013-9523-7

Anakinra, a recombinant human interleukin-1 receptor antagonist, inhibits apoptosis in experimental acute myocardial infarction.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12265-013-9523-7

Interleukin-1 blockade with anakinra to prevent adverse cardiac remodeling after acute myocardial infarction (Virginia Commonwealth University Anakinra Remodeling Trial [VCU-ART] Pilot study).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12265-013-9523-7

A tale of two diseases: atherosclerosis and rheumatoid arthritis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12265-013-9523-7

Human dermal mast cells contain and release tumor necrosis factor alpha, which induces endothelial leukocyte adhesion molecule 1

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12265-013-9523-7

CD4+ CD7- CD28- T cells are expanded in rheumatoid arthritis and are characterized by autoreactivity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12265-013-9523-7

Randomized, double-blind, placebo-controlled, pilot trial of infliximab, a chimeric monoclonal antibody to tumor necrosis factor-alpha, in patients with moderate-to-severe heart failure: results of the anti-TNF Therapy Against Congestive Heart Failu

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12265-013-9523-7

Testing the inflammatory hypothesis of atherothrombosis: scientific rationale for the cardiovascular inflammation reduction trial (CIRT).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12265-013-9523-7

Serum interleukin-6 levels in response to methotrexate treatment in psoriatic patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12265-013-9523-7

Inhibition of cytokine production by methotrexate. Studies in healthy volunteers and patients with rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12265-013-9523-7

Moving beyond JUPITER: will inhibiting inflammation reduce vascular event rates?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12265-013-9523-7

Atheroprotective effects of methotrexate on reverse cholesterol transport proteins and foam cell transformation in human THP-1 monocyte/macrophages

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12265-013-9523-7

Treatment with methotrexate inhibits atherogenesis in cholesterol-fed rabbits

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12265-013-9523-7

Systematic review and meta-analysis of methotrexate use and risk of cardiovascular disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12265-013-9523-7

Cyclo-oxygenase-2 (COX-2) expression at the site of recent myocardial infarction: friend or foe?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12265-013-9523-7

Augmented expression of cyclooxygenase-2 in human atherosclerotic lesions

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12265-013-9523-7

COX-1, COX-2, and COX-3 and the future treatment of chronic inflammatory disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12265-013-9523-7

Cyclo-oxygenase-2 (COX-2) inhibition reduces apoptosis in acute myocardial infarction.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12265-013-9523-7

Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12265-013-9523-7

Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12265-013-9523-7

Pleiotropic effects of statins.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12265-013-9523-7

MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12265-013-9523-7

Plasma lipid profile and incident ischemic stroke: the Atherosclerosis Risk in Communities (ARIC) study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12265-013-9523-7

Novel anti-inflammatory effect of statins: reduction of CD4+CD28null T lymphocyte frequency in patients with unstable angina.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12265-013-9523-7

Inflammation, pravastatin, and the risk of coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events (CARE) Investigators.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12265-013-9523-7

Inflammation and atherosclerosis: disease modulating therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12265-013-9523-7

Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12265-013-9523-7

C-reactive protein levels and outcomes after statin therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12265-013-9523-7

Statin therapy, LDL cholesterol, C-reactive protein, and coronary artery disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12265-013-9523-7

Effect of statin therapy on C-reactive protein levels: the pravastatin inflammation/CRP evaluation (PRINCE): a randomized trial and cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12265-013-9523-7

Rosuvastatin in the primary prevention of cardiovascular disease among patients with low levels of low-density lipoprotein cholesterol and elevated high-sensitivity C-reactive protein: rationale and design of the JUPITER trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12265-013-9523-7

High-sensitivity C-reactive protein and cardiovascular disease: a resolute belief or an elusive link?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12265-013-9523-7

By Jove! What is a clinician to make of JUPITER?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12265-013-9523-7

The JUPITER Trial: responding to the critics

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12265-013-9523-7

Pharmacogenetic determinants of statin-induced reductions in C-reactive protein.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12265-013-9523-7

Genetic determinants of statin-induced low-density lipoprotein cholesterol reduction: the Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER) trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12265-013-9523-7

Phospholipase A2 biochemistry

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12265-013-9523-7

Future role for selective phospholipase A2 inhibitors in the prevention of atherosclerotic cardiovascular disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12265-013-9523-7

Study design and rationale for the clinical outcomes of the STABILITY Trial (STabilization of Atherosclerotic plaque By Initiation of darapLadIb TherapY) comparing darapladib versus placebo in patients with coronary heart disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12265-013-9523-7

Relationship between cardiovascular risk factors and biomarkers with necrotic core and atheroma size: a serial intravascular ultrasound radiofrequency data analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12265-013-9523-7

Insights into the role of infection in atherogenesis and in plaque rupture

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12265-013-9523-7

Antibody response to chlamydial heat shock protein 60 is strongly associated with acute coronary syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12265-013-9523-7

Chlamydia pneumoniae in coronary atherosclerotic plaques and coronary instability

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12265-013-9523-7

Antibiotic treatment of atherosclerotic cardiovascular disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12265-013-9523-7

Azithromycin for the secondary prevention of coronary heart disease events: the WIZARD study: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12265-013-9523-7

Azithromycin for the secondary prevention of coronary events

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12265-013-9523-7

Antibiotic treatment of Chlamydia pneumoniae after acute coronary syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12265-013-9523-7

Randomised placebo controlled multicentre trial to assess short term clarithromycin for patients with stable coronary heart disease: CLARICOR trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12265-013-9523-7

Antibiotics in the prevention of heart attacks

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12265-013-9523-7

Potential therapeutic role of microRNAs in ischemic heart disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12265-013-9523-7

Study design and rationale for the Stabilization of pLaques usIng Darapladib—Thrombolysis in Myocardial Infarction (SOLID-TIMI 52) trial in patients after an acute coronary syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12265-013-9523-7

Altered status of CD4(+)CD25(+) regulatory T cells in patients with acute coronary syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12265-013-9523-7

High Telomerase Activity in Neutrophils From Unstable Coronary Plaques

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12265-013-9523-7

Delayed neutrophil apoptosis in patients with unstable angina: relation to C-reactive protein and recurrence of instability

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12265-013-9523-7

The Prognostic Value of C-Reactive Protein and Serum Amyloid A Protein in Severe Unstable Angina

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12265-013-9523-7

Perturbation of the T-Cell Repertoire in Patients With Unstable Angina

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12265-013-9523-7

Modulation of CD4 + CD28 null T Lymphocytes by Tumor Necrosis Factor-α Blockade in Patients With Unstable Angina

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12265-013-9523-7

Reduced antiplatelet effect of aspirin is associated with low-grade inflammation in patients with coronary artery disease

21 January 2018

1 reference

12 December 2020

Regional accumulations of T cells, macrophages, and smooth muscle cells in the human atherosclerotic plaque

1 reference

12 December 2020

High-dose atorvastatin after stroke or transient ischemic attack

1 reference

12 December 2020

How to use C-reactive protein in acute coronary care.

1 reference

12 December 2020

CDC/AHA Workshop on Markers of Inflammation and Cardiovascular Disease: Application to Clinical and Public Health Practice: clinical use of inflammatory markers in patients with cardiovascular diseases: a background paper

1 reference

12 December 2020

Patients With Acute Coronary Syndrome Show Oligoclonal T-Cell Recruitment Within Unstable Plaque

1 reference

12 December 2020

Influence of nebivolol and metoprolol on inflammatory mediators in human coronary endothelial or smooth muscle cells. Effects on neointima formation after balloon denudation in carotid arteries of rats treated with nebivolol

1 reference

12 December 2020

1 reference

12 December 2020

Molecular and cellular mechanisms of the thrombotic complications of atherosclerosis

1 reference

12 December 2020

The effect of cryo-maze procedure on early and intermediate term outcome in mitral valve disease: case matched study

1 reference

12 December 2020

Inhibition of cyclooxygenase-2 improves cardiac function in myocardial infarction

1 reference

12 December 2020

Cellular actors, Toll-like receptors, and local cytokine profile in acute coronary syndromes

1 reference

12 December 2020

Inflammation and cardiovascular disease: role of the interleukin-1 receptor antagonist

1 reference

12 December 2020

Cyclooxygenase-2 is widely expressed in atherosclerotic lesions affecting native and transplanted human coronary arteries and colocalizes with inducible nitric oxide synthase and nitrotyrosine particularly in macrophages

1 reference

12 December 2020

Emerging role of interleukin-1 in cardiovascular diseases.

1 reference

12 December 2020

Relation of C-reactive protein and coronary heart disease in the MRFIT nested case-control study. Multiple Risk Factor Intervention Trial

1 reference

12 December 2020

Inhibition of secretory phospholipase A(2) in patients with acute coronary syndromes: rationale and design of the vascular inflammation suppression to treat acute coronary syndrome for 16 weeks (VISTA-16) trial

1 reference

12 December 2020

Interleukin-1β inhibition and the prevention of recurrent cardiovascular events: rationale and design of the Canakinumab Anti-inflammatory Thrombosis Outcomes Study (CANTOS)

1 reference

12 December 2020

Synergistic proinflammatory effects of the antiviral cytokine interferon-alpha and Toll-like receptor 4 ligands in the atherosclerotic plaque

1 reference

12 December 2020

Pathogens and atherosclerosis: update on the potential contribution of multiple infectious organisms to the pathogenesis of atherosclerosis

1 reference

12 December 2020

Methotrexate in atherogenesis and cholesterol metabolism

1 reference

12 December 2020

Activated platelets induce endothelial secretion of interleukin-8 in vitro via an interleukin-1-mediated event

1 reference

12 December 2020

Influence of cholesterol-lowering on plasma membrane lipids and function

1 reference

12 December 2020